Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
2.85    -0.05 (-1.72%)
Bid:
2.60
Ask:
3.10
Spread: 0.50 (19.231%)
Market Cap: £20.60m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

Partner Update

25 Oct 2010 07:00

RNS Number : 9104U
Amphion Innovations PLC
25 October 2010
Β 

ο»Ώ

Β 

Β 

EU certification for colour X ray technology will see the end of liquid flight ban

Major milestone for Amphion Partner Company, Kromek

Β 

London and New York, 25 October 2010 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that its Partner Company, Kromek, which specialises in the development of disruptive technology solutions for a range of commercial markets including airport and border security, has received official European Union (EU) certification to provide colour x-ray liquid detection systems to all European airports.

Β 

By April 2011, liquid items bought in transit (i.e. duty free purchases) will be allowed on board, providing the appropriate security measures, such as screening, are in place at the airports concerned. The results of the European Civil Aviation Conference (ECAC) led trials establish that the technology is ready to allow the 2011 deadline to be met by the airports. By April 2013, the ban will be lifted completely, allowing the carriage of liquids on flights across Europe.

Β 

Kromek's Bottle Scanner has qualified as a Category B device that has achieved Type 1 and Type 2 100% capability and has been officially tested, verified and authorised by ECAC. As of now, all EU airports are free to buy and implement Kromek's Bottle Scanner product, opening the company to the multi million dollar airport security market.Β 

Β 

The move marks a breakthrough in airport security. As the threat from liquid threat has become greater, airport security officials are seeking appropriate technology to mitigate this threat. For the first time, airports can purchase tested, approved, and secure technology that will allow authorities to relax the ban on liquid on flights.

Β 

Dr. Arnab Basu, CEO of Kromek, said, "It's a significant milestone for Kromek as the approved listing is vindication that colour x-ray detection has been proven. The next generation of X-ray technology has arrived, with a market ready machine that can detect liquid threat.

Β 

"The threat from Liquid, Aerosol and Gel (LAG) based explosives became apparent in August 2006 following discovery of a plot to use such devices aboard multiple transatlantic flights. Although Kromek had not set out to produce such equipment we were quick to realise with our capabilities we had the versatility to produce a solution for this market need.

Β 

Kromek's verified and approved solution effectively guards against such a possibility. It is a major step forward in the fight against global terrorism where liquid is increasingly becoming a common tool for terrorist use."

Β 

Kromek's revolutionary technology signals a new era in colour x-ray detection, and a market-changing development in aviation security. The company is introducing to the sector a pioneering form of detection, which has been likened to the advent of colour TV, from black and white, in terms of significance and market potential.

Β 

Richard Morgan, CEO of Amphion and Chairman of Kromek, said, "This approval by the ECAC is a major milestone for Kromek. Kromek's proven technology meets a previously unmet need in airport security. Kromek's Bottle Scanner should make a major contribution to a more efficient security system within the European markets."

Β 

Dr. Basu concluded, "The next year and beyond is extremely exciting for us. Kromek will continue to see strong growth over the coming years as our innovative solutions to many previously intractable problems captures the imagination.Β  Our groundbreaking technology not only provides products to the airline security market but has the opportunity for development into a range of products for many highly lucrative markets such as medical and industrial fields."

Β 

For further information please contact

Amphion Innovations plcCharlie Morgan +1Β (212)Β 210Β 6224

Cardew GroupTim Robertson/ James Milton+44 20 7930 0777

Charles Stanley (Nominated Adviser) Mark Taylor+44Β 20Β 7149Β 6000

Β 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

AboutΒ Kromek

Kromek was spun out of Durham University's physics department and specialises in the development of disruptive technology solutions for a broad range of commercial markets. It is currently pioneering digital colour imaging for x-rays and advanced 3D imaging for the medical, security, industrial inspection and defence markets. The company has successfully pioneered a revolutionary 3D x-ray technology, which has huge commercial benefits for a range of sectors, especially the airline security industry, where it is uniquely placed to fulfil an increasing, necessary worldwide demand for liquid explosive detection at airports.

On the web: www.kromek.com

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRAFEAFWEFSSEIS
Date   Source Headline
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.